Titanium clasp fabricated by selective laser melting,CNC milling,and conventional casting: a comparative in vitro study

Purpose

This study aimed to investigate the effects of selective laser melting (SLM), milling methods, and casting on the behavior of titanium clasp.

RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D

There are no reports on the relationship between familial medullary thyroid carcinoma (FMTC) associated with cutaneous amyloidosis (CA) and RET or OSMR/IL31RA gene mutations. In this study, we investigated a Chinese family with FMTC/CA and found a recurrent RET c.2671T>G (p.S891A) mutation in six of 17 family members. Three of the six p.S891A mutation carriers presented with medullary thyroid carcinoma (MTC). Of them, three (two with and one without MTC) were diagnosed as having combined lichen/macular biphasic CA. We also identified a novel RET variant, c.1573C>T (p.R525W) in five members. Of them, three carriers had no evidence of thyroid/skin or basal serum/stimulated calcitonin abnormalities. In vitro cell proliferation assay indicated that oncogenic activity of RET p.S891A was slightly enhanced by p.R525W, whereas p.R525W alone had no effect on cell proliferation. Meanwhile, we identified a novel OSMR variant, c.1538G>A (p.G513D) in seven members. We noticed that three OSMR p.G513D carriers presenting with CA also had the RET p.S891A mutation. Our investigation indicated that the RET p.S891A mutation combined with OSMR p.G513D may underlie a novel phenotype manifesting as FMTC and CA.     

Copy number changes of 4-gene set may predict early relapse in advanced epithelial ovarian cancer after initial platinum-paclitaxel chemotherapy

For advanced epithelial ovarian cancer (EOC), time to recurrence (TTR) is an important indicator to gauge the therapeutic efficacy of postoperative adjuvant chemotherapy. Our objective was to determine the genes that could potentially distinguish patients with short versus long TTR after initial administration of platinum-paclitaxel combination chemotherapy in advanced EOC. Tumor samples of 159 patients were obtained during the primary cytoreduction. Array comparative genomic hybridization (CGH) was carried with genomic DNA from 17 EOC samples (8 with TTR > 15 months and 9 with TTR ≤ 6 months) to screen candidate gene set, copy-number changes (CNC) of which were significantly different between early and late relapse cases. Seventeen candidate genes were identified by array CGH. The analysis of consistency between real-time PCR and array CGH revealed that 4 genes displayed consistent results, namely GSTT1, ISG20L1, STARD5 and FREM1. In a 142-case validation set, CNC of 4 candidate genes was evaluated and verified by real-time PCR. Sixty five point five percent of the patients were correctly divided into early (TTR ≤ 10 months) and late (TTR > 10 months) recurrent group by CNC of the 4 genes using discriminant analysis. The results showed that CNC of 4-gene set could potentially determine early (TTR ≤ 10 months) or late relapse (TTR > 10 months) after initial platinum-paclitaxel combination chemotherapy in advanced EOC.     

微创穿刺术治疗高血压脑出血时间窗的研究

目的:研究微创穿刺术治疗高血压脑出血的最佳时机.方法:41例高血压脑出血随机分为4组,即手术距发病时间<6 h组、6～12 h组、12～18 h组和18～24 h组;用再出血率、近期疗效、远期疗效、病死率、转归优良率等疗效评价指标进行组间比较.结果:再出血等并发症发生率无显著差异;3个月时的临床转归优良率:<6 h组>6～12 h组和12～18 h组>18～24 h组(P<0.05),18～24 h组病死率最高,达30%(3/10).结论:高血压脑出血发病后6 h内是微创穿刺术治疗的最佳时机.     

番石榴叶提取物对三硝基苯磺酸诱导大鼠结肠炎结肠组织的保护作用

目的:研究番石榴叶提取物对大鼠结肠炎组织损伤的保护作用及其机制.方法:用健康Wistar大鼠建立大鼠结肠炎模型,灌胃用药2 wk后,评价大鼠结肠黏膜损伤指数(CMDI),检测结肠组织髓过氧化物酶(MPO)及超氧化物歧化酶(SOD)活性、丙二醛(MDA)含量和细胞肿瘤因子(TNF)、白细胞介素-8(IL-8)、白细胞介素-10(IL-10)水平.结果:不同剂量番石榴叶提取物(200,500,800 mg/kg)灌胃均能不同程度降低模型大鼠CMDI(2.62±0.47,2.06±0.54,1.83±0.43 vs 3.15±0.39,P＜0.05,P＜0.01,P＜0.01),MPO活性(2240.78±479.26,2078.42±377.91,1748.85±236.71 nkat/g vs 2695.37±624.79 nkat/g P＜0.05,P＜0.01,P＜0.01),减少MDA含量(2.16±0.41,1.97±0.35,1.96±0.30,P＜0.05,P＜0.01,P＜0.01),提高SOD活性(3618.06±538.44,3756.92±577.45,4197.51±375.74 nkat/g vs 2663.37±603.79,P＜0.05,P＜0.01,P＜0.01),降低TNF(2.65±0.40,2.51±0.47,2.21±0.41 μg/L vs 3.30±0.63 μg/L,P＜0.05,P＜0.01,P＜0.01)、IL-8(1.20±0.33,1.05±0.24,0.92±0.13 μg/L vs 1.53±0.38 μg/L,P＜0.05,P＜0.01,P＜0.01)、IL-10(39.36±9.65,50.26±11.32.59.68±13.65 ng/L vs 30.74±12.91 ng/L,P＜0.05,P＜0.01,P＜0.01)水平,且与用药剂量呈一定量效关系.结论:番石榴叶提取物通过拮抗氧化、免疫调节、损伤修复作用缓解结肠炎大鼠炎症反应,减轻结肠损伤.     

慢性乙型肝炎患者血清脂质水平与病理分级分期的关系

目的:探讨慢性乙型肝炎肝组织病变严重程度与血清脂质水平的关系．方法:采用全自动生化分析仪测定130例慢性乙型肝炎患者和30例正常人血清总胆固醇 (TC)、甘油三酯(TG)、高密度脂蛋白胆固醇 (HDL-C)、低密度脂蛋白胆固醇(LDI-C)、极低密度脂蛋白胆固醇(VLDL-C),并与慢性乙型肝炎患者肝组织病理分级分期进行对比分析．结果:慢性乙型肝炎患者血清的脂质水平随着肝组织炎症程度加重、肝组织纤维分期升高而逐渐降低,较重的肝组织炎症活动程度 (G3、G4)、较重的肝组织纤维分期(S4)与对照组比较,有显著差异(P<0．05或<0．01),较轻的肝组织炎症活动程度(G1、G2)、较轻的肝组织纤维分期(S0、S1、S2、S3)与对照组比较,差异不显著(P>0．05)．结论:测定血清脂质水平对判断较重的慢性肝炎肝组织实质细胞的损害和预后估计有一定的价值．     

针刀治疗第三腰椎横突综合征:随机对照观察

目的:探讨针刀对第三腰椎横突综合征的治疗效果。方法:将第三腰椎横突综合征患者180例按区组随机法分为针刀治疗组、阻滞组及针刺对照组,分别进行针刀、阻滞及针刺治疗。治疗前、后分别按“腰椎疾患治疗成绩评分表”评分,对测评结果进行统计学分析。结果:治疗前后成绩评分,针刀组治疗前(9.6±2.7)分,治疗后(23.0±5.7)分,改善指数0.56±0.61;阻滞组治疗前(9.9±2.8)分,治疗后(15.1±7.1)分,改善指数0.33±0.27;针刺组治疗前(9.7±2.9)分,治疗后(13.2±6.5)分,改善指数0.24±0.21。3组治疗前后评分,针刀治疗组优于阻滞及针刺对照组(P<0.001,t=18.32,5.65,4.21);3组疗效比较,针刀治疗组明显优于阻滞及针刺对照组(P<0.01,χ2=38.1,41.1);3组治疗后评分均比治疗前分值差异有显著性意义(P<0.001,t=6.39,11.85)。结论:与阻滞、针刺治疗组相比,针刀是保守治疗第三腰椎横突综合征值得采用的有效方法之一。     

ICP-MS法测定注射用头孢美唑钠中31种元素杂质的含量

摘 要 目的：建立电感耦合等离子体质谱（ICP-MS）法,测定注射用头孢美唑钠中的31种具有潜在风险的元素杂质：砷（As）、镉（Cd）、汞（Hg）、铅（Pb）、钴（Co）、镍（Ni）、钒（V）、金（Au）、铱（Ir）、锇（Os）、钯（Pd）、铂（Pt）、铑（Rh）、钌（Ru）、银（Ag）、硒（Se）、铊（Tl）、钡（Ba）、钼（Mo）、铬（Cr）、铜（Cu）、锂（Li）、锑（Sb）、锡（Sn）、硼（B）、铝（Al）、硅（Si）、钛（Ti）、锰（Mn）、铁（Fe）,锌（Zn）的含量。方法：采用Agilent 8900 ICP-MS Triple Quad电感耦合等离子体质谱仪,运用碰撞模式消除双电荷干扰,以高基体样品进样系统模式进样,通过在线内标方式消除基质效应,样品稀释直接进样测定。结果：该方法能同时测定31种元素杂质含量,其线性关系良好（r ＞ 0.99）、重复性试验的RSD小于20%（n = 6）、回收率在70%～140%（n = 9）,均满足USP 43 < 233 > 方法学验证碰撞模式的要求。应用该方法测定了20批来自不同生产企业的国产制剂及1批原研制剂中上述元素的含量。结论：国产及原研制剂中元素杂质含量均低于限度的30%,风险可控;所建立的方法操作简便,准确灵敏,专属性强,重复性好,可为化学药品中元素杂质控制方法提供参考。本试验对国评样品的元素杂质迁移情况开展筛查,不仅能够掌握注射用头孢美唑钠质量整体水平,并且可以为监管部门对上市后药品再评价提供技术储备和数据支持。     

Two new clerodane diterpenoids and a new pyran-2-one derivative with anti-neuroinflammatory activities from Croton crassifolius

Journal of Natural Medicines - Two new clerodane diterpenoids (1 and&nbsp;2), a new pyran-2-one derivative (3), along with five known compounds (4?8), were isolated from Croton...